CIK 0000014272
- Large accelerated filer
BRISTOL MYERS SQUIBB CO
Sign in to watch- Ticker
- BMY
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 220790350
- Phone
- +1 609-252-4621
- Business address
- ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NJ, 08543
Securities
- BMY Bristol-Myers Squibb Company Common Stock NYSE
- CELG-RI Rights NYSE
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $677,826
- in 3 filings
Net −$677,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-12-01 | Eid Joseph SVP,Head Glob. Medical Affairs | Exercise or conversion · Restricted Stock Units | −2,825 | 2,826 | ||
| 2020-11-25 | von Autenried Paul EVP, Chief Information Officer | Sale | −3 | $63.50 | $191 | 126,698.07 |
| 2020-11-24 | Dubow Adam SVP,ChiefCompliance&EthicsOff. | Sale | −900 | $63.39 | $57K | 15,186.15 |
| 2020-11-24 | von Autenried Paul EVP, Chief Information Officer | Sale | −20,000 | $62.75 | $1.3M | 126,701.07 |
| 2020-11-23 | VESSEY RUPERT EVP, Research & Early Dev. | Sale | −13,421 | $61.34 | $823K | 37,922 |
| 2020-11-19 | VESSEY RUPERT EVP, Research & Early Dev. | Sale | −10,579 | $61.25 | $648K | 46,142 |
| 2020-11-19 | VESSEY RUPERT EVP, Research & Early Dev. | Exercise or conversion | +14,515 | $54.94 | $797K | 60,657 |
| 2020-11-19 | VESSEY RUPERT EVP, Research & Early Dev. | Exercise or conversion | +12,233 | $54.29 | $664K | 72,890 |
| 2020-11-19 | VESSEY RUPERT EVP, Research & Early Dev. | Exercise or conversion | +8,489 | $44.70 | $379K | 81,379 |
| 2020-11-19 | VESSEY RUPERT EVP, Research & Early Dev. | Exercise or conversion | +8,489 | $47.81 | $406K | 89,868 |
| 2020-11-19 | VESSEY RUPERT EVP, Research & Early Dev. | Exercise or conversion | +8,487 | $38.41 | $326K | 98,355 |
| 2020-11-19 | VESSEY RUPERT EVP, Research & Early Dev. | Sale | −47,012 | $61.31 | $2.9M | 51,343 |
| 2020-11-19 | VESSEY RUPERT EVP, Research & Early Dev. | Exercise or conversion · Option (right to buy) | −14,515 | 0 | ||
| 2020-11-19 | VESSEY RUPERT EVP, Research & Early Dev. | Exercise or conversion · Option (right to buy) | −12,233 | 12,233 | ||
| 2020-11-19 | VESSEY RUPERT EVP, Research & Early Dev. | Exercise or conversion · Option (right to buy) | −8,489 | 16,980 | ||
| 2020-11-19 | VESSEY RUPERT EVP, Research & Early Dev. | Exercise or conversion · Option (right to buy) | −8,489 | 16,980 | ||
| 2020-11-19 | VESSEY RUPERT EVP, Research & Early Dev. | Exercise or conversion · Option (right to buy) | −8,487 | 16,981 | ||
| 2020-10-30 | AHMED NADIM EVP and President, Hematology | Exercise or conversion | +4,650 | 30,680 | ||
| 2020-10-30 | AHMED NADIM EVP and President, Hematology | Shares withheld for taxes | −2,291 | $58.45 | $134K | 28,389 |
| 2020-10-30 | AHMED NADIM EVP and President, Hematology | Exercise or conversion · Restricted Stock Units | −4,650 | 0 |
Page 87 of 90 · 1,795 trades